Hoth Therapeutics, Inc. (HOTH) announced on Thursday encouraging results from the initial human treatment using its innovative therapeutic, HT-001, for epidermal growth factor receptor inhibitor (EGFRI)-associated papulopustular eruptions.In the study, a 59-year-old female patient undergoing treatment for metastatic breast cancer demonstrated significant improvement within a week of starting the therapy.The biotechnology firm has also commenced a Phase 2a clinical trial to further assess the efficacy and safety of HT-001 for treating EGFRI-related skin toxicities.As of now, Hoth’s stock is trading at $1.32, reflecting a 90.04 percent increase on the Nasdaq.The material has been provided by InstaForex Company – www.instaforex.com
Latest posts by Insta Forex (see all)
- Bicycle Therapeutics Reveals Updated Clinical Results Across Oncology Pipeline - September 14, 2024
- J&J: RYBREVANT + Chemotherapy Shows Strong Benefits And Improved Survival In Phase 3 NSCLC Trial - September 14, 2024
- J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer - September 14, 2024
